Thursday 16 October, 2025
Introduction/Objectives: Carbapenem-resistant Gram-negative bacteria such as Enterobacterales and Pseudomonas aeruginosa are considered critical or high priority pathogens by the updated…
Read morePoster: Drug/Disease Modelling - Infection
Evaluating the Relationship Between Experimental EC50 Values and Mechanism-Based Model Parameters in Viral Dynamics models
Thursday 16 October, 2025
Introduction There exists an urgent need for new antiviral therapies against emerging viruses[1]. The empirically derived half-maximal effective concentration (EC50)…
Read morePopulation Pharmacokinetics Modelling of Ibrexafungerp Using Data from Healthy Volunteers
Thursday 16 October, 2025
Objectives: Ibrexafungerp is a triterpenoid antifungal agent that is under development for the treatment of adults with invasive Candida infections…
Read moreA PK/PD workflow to support the selection of empirical antibiotic combination therapies: application to neonatal sepsis
Thursday 16 October, 2025
Objectives: Severe acute infections are often treated empirically with a combination of antibiotics to increase the likelihood of covering the…
Read moreINTEGRATED POPULATION PKPD MODELLING OF VIRAL DYNAMICS AND HOST IMMUNE RESPONSE IN HIV PATIENTS UNDERGOING ANTIRETROVIRAL MONOTHERAPY
Thursday 16 October, 2025
Introduction Human immunodeficiency virus (HIV) remains a global health challenge, with up to 75% of infected individuals undergoing antiretroviral therapy…
Read moreDo differences in pharmacokinetics overcome resemblances in immune system characteristics in cynomolgus macaques for the evaluation of antitubercular drugs?
Thursday 16 October, 2025
Introduction: The tuberculosis (TB) drug development pipeline is being re-populated with drugs, like nitroimidazoles, shortening TB therapy and having efficacy…
Read moreIn vitro-in silico characterisation of host-directed therapeutics combined with antimicrobials in tuberculosis
Thursday 16 October, 2025
Objectives: The ERA4TB consortium [1] has established a robust in vitro benchmarking platform that allows the detailed characterisation of compounds…
Read morePharmacokinetics of Flucytosine in HIV-positive adults with cryptococcal meningitis adults in Africa
Thursday 16 October, 2025
Introduction & Objectives: Flucytosine (5-FC) is commonly used in combination therapy for the treatment of cryptococcal meningitis. Historically, its use…
Read morePopulation pharmacokinetics of orally administered letermovir in real world allogeneic hematopoietic cell transplantation recipients
Thursday 16 October, 2025
Introduction: Cytomegalovirus (CMV) reactivation remains a major infectious complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), contributing to significant morbidity…
Read morePopulation pharmacokinetic modelling as a screening tool to expedite evidence for hard-to-study populations: a case study of atazanavir/ritonavir in people with HIV.
Thursday 16 October, 2025
Objectives: Access to life-saving antiretroviral therapy (ART) in hard-to-study populations, such as pregnant women, children, adolescents and individuals with extreme…
Read more